Analyst firms · J.P. Morgan · DOCS

J.P. Morgan DOCS price target and rating history

Doximity Inc. (DOCS) · Technology

J.P. Morgan rates Doximity Inc. (DOCS) Neutral with a $25 price target, as of its latest action on Apr 25, 2024. It has published 4 rating actions on DOCS since July 2021, including 1 upgrade and 2 downgrades. Across 12 firms with a DOCS price target in the last 12 months, the median target is $27.

Current rating

Neutral

Price target

$25

Median target, all firms

$27

Actions on DOCS

4

J.P. Morgan price target on DOCS

Every J.P. Morgan rating on DOCS

• Apr 25, 2024
  UpgradeJ.P. Morgan upgrades to Neutral from Underweight, price target $25
• Dec 14, 2021
  DowngradeJ.P. Morgan downgrades to Underweight from Neutral, price target $70 to $60
• Aug 26, 2021
  DowngradeJ.P. Morgan downgrades to Neutral from Overweight, price target $70
• Jul 19, 2021
  InitiateJ.P. Morgan starts coverage at Overweight, price target $60

How other firms rate DOCS

Each firm's latest rating and stated target in the last 12 months.

Questions about J.P. Morgan and DOCS

What is J.P. Morgan's price target for DOCS?

J.P. Morgan's latest stated price target for Doximity Inc. (DOCS) is $25, from its action on Apr 25, 2024.

What is J.P. Morgan's rating on DOCS?

J.P. Morgan rates DOCS Neutral, a neutral rating, as of Apr 25, 2024.

When did J.P. Morgan last change its view on DOCS?

On Apr 25, 2024, J.P. Morgan upgrades to Neutral from Underweight, price target $25.

How does J.P. Morgan's DOCS target compare with other analysts?

Across 12 firms with a DOCS price target in the last 12 months, the median target is $27.

More DOCS rating histories

• Wells Fargo7
• BofA Securities6
• Barclays4
• KeyBanc Capital Markets3
• Robert W. Baird3
• BTIG3
• Jefferies3
• Truist Securities3
• Evercore ISI3
• Canaccord Genuity4
• Morgan Stanley8
• Raymond James5
• Goldman Sachs6
• Piper Sandler4
• Leerink Partners4
• Needham6
• Guggenheim3

All J.P. Morgan ratingsDOCS news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.